← Leaderboards
Nicholas Muzyczka
University Of Florida
$10,997,810
Attributed
$12,330,271
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–17$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$44,961,841 · 15
By mechanism
P01$36,977,627 · 9
P50$4,422,950 · 4
R01$3,561,264 · 2
Top collaborators
- Mavis Agbandje-Mckenna5 shared
- Robert Mckenna5 shared
Most similar at University Of Florida
Same institution · by research overlap
- Richard O Snyder$2,589,972
- Scott B Hansen$5,512,079
- Robert McKenna$4,675,159
Others in their field
Top investigators on “Transfection /Expression Vector”
- William W Hauswirth · University Of Florida$14,472,513
- Kenneth G Cornetta · Indiana Univ-Purdue Univ At Indianapolis$10,466,261
- Klaus H. Kaestner · University Of Pennsylvania$8,467,407
- David T Curiel · University Of Alabama At Birmingham$8,321,535
- Timothy A Cross · Florida State University$7,979,166
- John H Wolfe · Children'S Hospital Of Philadelphia$7,103,743
Research focus
Transfection /Expression VectorGene TherapyVectorCapsidAdeno Associated Virus GroupCellsAdeno-Associated Viral VectorGene TransferResearch StudyMutantTraffickingProteinsCryoelectron MicroscopyProductionGenesGene ExpressionSiteRecombinant VirusSerotypingGeneticDependovirusIn VivoPositioning AttributeRecombinant Adeno-Associated Virus (Raav)
Grant awards (72)
The role of pH and protease activity in AAV viral transduction$477,173
R01 · FY2017 · GM
The role of pH and protease activity in AAV viral transduction$477,173
R01 · FY2016 · GM
The role of pH and protease activity in AAV viral transduction$477,173
R01 · FY2015 · GM
The role of pH and protease activity in AAV viral transduction$90,000
R01 · FY2015 · GM
The role of pH and protease activity in AAV viral transduction$477,173
R01 · FY2014 · GM
Identifying and testing new targets for Parkinson Disease gene therapy$310,918
R01 · FY2014 · NS · contact PI
Identifying and testing new targets for Parkinson Disease gene therapy$303,067
R01 · FY2013 · NS · contact PI
Biology of adeno-associated viral vectors$176,029
P01 · FY2013 · HL · contact PI
Gene Therapy for Lung and Cardiovascular Disease$2,015,232
P01 · FY2012 · HL · contact PI
Identifying and testing new targets for Parkinson Disease gene therapy$314,059
R01 · FY2012 · NS · contact PI
Biology of adeno-associated viral vectors$185,697
P01 · FY2012 · HL · contact PI
Gene Therapy for Lung and Cardiovascular Disease$2,015,232
P01 · FY2011 · HL · contact PI
Identifying and testing new targets for Parkinson Disease gene therapy$314,059
R01 · FY2011 · NS · contact PI
Biology of adeno-associated viral vectors$189,885
P01 · FY2011 · HL · contact PI
Gene Therapy for Lung and Cardiovascular Disease$2,014,490
P01 · FY2010 · HL · contact PI
Identifying and testing new targets for Parkinson Disease gene therapy$320,469
R01 · FY2010 · NS · contact PI
Biology of adeno-associated viral vectors$190,637
P01 · FY2010 · HL · contact PI
Gene Therapy for Lung and Cardiovascular Disease$2,015,770
P01 · FY2009 · HL · contact PI
Biology of adeno-associated viral vectors$193,937
P01 · FY2009 · HL · contact PI
Gene Therapy for Lung and Cardiovascular Disease$2,036,433
P01 · FY2008 · HL · contact PI
Adeno-Associated Virus Gene Transfer to Nervous System$1,279,616
P01 · FY2008 · NS · contact PI
alpha synuclein function$372,499
P01 · FY2008 · NS · contact PI
Core--Vector$328,064
P01 · FY2008 · NS · contact PI
Biology of Adeno-Associated Viral Vectors$292,932
P01 · FY2008 · HL · contact PI
Adeno-Associated Virus Gene Transfer to Nervous System$1,293,187
P01 · FY2007 · NS · contact PI
alpha synuclein function$377,025
P01 · FY2007 · NS · contact PI
Core--Vector$329,759
P01 · FY2007 · NS · contact PI
Biology of Adeno-Associated Viral Vectors$289,920
P01 · FY2007 · HL · contact PI
Gene Therapy for Lung and Cardiovascular Disease$2,047,683
P01 · FY2006 · HL · contact PI
Adeno-Associated Virus Gene Transfer to Nervous System$1,291,733
P01 · FY2006 · NS · contact PI
alpha synuclein function$369,274
P01 · FY2006 · NS · contact PI
AAV capsid assembly, viral entry, and viral tropism$219,976
P01 · FY2006 · HL · contact PI
Biology of Adeno-Associated Viral Vectors$199,381
P01 · FY2006 · HL · contact PI
Gene Therapy for Lung and Cardiovascular Disease$2,054,950
P01 · FY2005 · HL
Adeno-Associated Virus Gene Transfer to Nervous System$1,297,879
P01 · FY2005 · NS
alpha synuclein function$360,500
P01 · FY2005 · NS
AAV capsid assembly, viral entry, and viral tropism$319,048
P01 · FY2005 · HL
Biology of Adeno-Associated Viral Vectors$193,575
P01 · FY2005 · HL
Adeno-Associated Virus Gene Transfer to Nervous System$26,550
P01 · FY2005 · NS
Adeno-Associated Virus Gene Transfer to Nervous System$21,300
P01 · FY2005 · NS
Gene Therapy for Lung and Cardiovascular Disease$1,992,904
P01 · FY2004 · HL
Adeno-Associated Virus Gene Transfer to Nervous System$1,296,601
P01 · FY2004 · NS
alpha synuclein function$349,848
P01 · FY2004 · NS
Core--Vector$312,107
P01 · FY2004 · NS
Biology of Adeno-Associated Viral Vectors$188,011
P01 · FY2004 · HL
Administrative Core$49,159
P01 · FY2004 · NS
Adeno-Associated Virus Gene Transfer to Nervous System$29,400
P01 · FY2004 · NS
Gene Therapy for Lung and Cardiovascular Disease$1,936,840
P01 · FY2003 · HL
Gene Therapy for Lung and Cardiovascular Disease$1,906,199
P01 · FY2002 · HL
GENE TRANSFER TO THE NERVOUS SYSTEM$924,319
P01 · FY2002 · NS
AAV VECTOR DEVELOPMENT$242,910
P01 · FY2002 · NS
AAV capsid assembly, viral entry, and viral tropism$219,976
P01 · FY2002 · HL
CORE--VECTOR FACILITY$187,476
P01 · FY2002 · DK
Gene Therapy for Lung and Cardiovascular Disease$181,000
P01 · FY2002 · HL
GENE THERAPY USING VIRAL VECTOR FOR LU AND CARDIOVA$1,434,081
P50 · FY2001 · HL
GENE TRANSFER TO THE NERVOUS SYSTEM$915,023
P01 · FY2001 · NS
AAV VECTOR DEVELOPMENT$283,370
P01 · FY2001 · NS
CORE--VECTOR$219,976
P50 · FY2001 · HL
GENETIC AND BIOCHEMICAL ANALYSIS OF AAV TRANSCRIPTIONAL CONTROL$219,976
P50 · FY2001 · HL
CORE--PILOT/FEASIBILITY STUDIES$219,976
P50 · FY2001 · HL
CORE--VECTOR FACILITY$187,476
P01 · FY2001 · DK
GENE TRANSFER TO THE NERVOUS SYSTEM$75,000
P01 · FY2001 · NS
AAV VECTOR DEVELOPMENT$0
P01 · FY2001 · NS
GENE THERAPY USING VIRAL VECTOR FOR LU AND CARDIOVA$1,520,543
P50 · FY2000 · HL
GENE TRANSFER TO THE NERVOUS SYSTEM$909,605
P01 · FY2000 · NS
AAV VECTOR DEVELOPMENT$283,370
P01 · FY2000 · NS
CORE--VECTOR$269,466
P50 · FY2000 · HL
GENETIC AND BIOCHEMICAL ANALYSIS OF AAV TRANSCRIPTIONAL CONTROL$269,466
P50 · FY2000 · HL
CORE--PILOT/FEASIBILITY STUDIES$269,466
P50 · FY2000 · HL
AAV VECTOR DEVELOPMENT$221,364
P01 · FY2000 · NS
CORE--VECTOR FACILITY$187,476
P01 · FY2000 · DK
GENE TRANSFER TO THE NERVOUS SYSTEM$100,000
P01 · FY2000 · NS